Nothing Special   »   [go: up one dir, main page]

BR112018010499A8 - método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, população de células in vitro, método para produzir uma população de células, e população de células - Google Patents

método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, população de células in vitro, método para produzir uma população de células, e população de células

Info

Publication number
BR112018010499A8
BR112018010499A8 BR112018010499A BR112018010499A BR112018010499A8 BR 112018010499 A8 BR112018010499 A8 BR 112018010499A8 BR 112018010499 A BR112018010499 A BR 112018010499A BR 112018010499 A BR112018010499 A BR 112018010499A BR 112018010499 A8 BR112018010499 A8 BR 112018010499A8
Authority
BR
Brazil
Prior art keywords
cell population
producing
virus
vaccine composition
replicating
Prior art date
Application number
BR112018010499A
Other languages
English (en)
Other versions
BR112018010499A2 (pt
Inventor
Bean Andrew
William Lowenthal John
Fernando Malaver-Ortega Luis
A Tripp Ralph
Original Assignee
Commw Scient Ind Res Org
Univ Georgia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015904851A external-priority patent/AU2015904851A0/en
Application filed by Commw Scient Ind Res Org, Univ Georgia filed Critical Commw Scient Ind Res Org
Publication of BR112018010499A2 publication Critical patent/BR112018010499A2/pt
Publication of BR112018010499A8 publication Critical patent/BR112018010499A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C12N2760/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18211—Henipavirus, e.g. hendra virus
    • C12N2760/18251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção se refere a métodos para replicar vírus in vitro. em particular, a invenção se refere a uma população de células geneticamente modificadas e/ou a uma população de células tratadas com um composto exógeno, em que as células são capazes de produzir mais vírus que as células sem a modificação genética e/ou sem tratamento com o composto exógeno. a invenção também se refere a métodos para produzir populações de tais células, assim como ao uso dos vírus obtidos para preparar composições de vacina.
BR112018010499A 2015-11-24 2016-11-23 método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, população de células in vitro, método para produzir uma população de células, e população de células BR112018010499A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015904851A AU2015904851A0 (en) 2015-11-24 Production of viruses in cell culture
PCT/AU2016/051147 WO2017088018A1 (en) 2015-11-24 2016-11-23 Production of viruses in cell culture

Publications (2)

Publication Number Publication Date
BR112018010499A2 BR112018010499A2 (pt) 2018-11-13
BR112018010499A8 true BR112018010499A8 (pt) 2019-02-26

Family

ID=58762866

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010499A BR112018010499A8 (pt) 2015-11-24 2016-11-23 método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, população de células in vitro, método para produzir uma população de células, e população de células

Country Status (10)

Country Link
US (3) US11174466B2 (pt)
EP (1) EP3380611A4 (pt)
JP (2) JP7189017B2 (pt)
KR (1) KR20180081615A (pt)
CN (1) CN108603188A (pt)
AU (2) AU2016361455A1 (pt)
BR (1) BR112018010499A8 (pt)
CA (1) CA3005989A1 (pt)
MX (2) MX2018006373A (pt)
WO (1) WO2017088018A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018006386A (es) 2015-11-24 2018-11-09 Commonwealth Scient And Industrial Reseach Organisation Produccion de virus en evos aviares.
WO2017088018A1 (en) 2015-11-24 2017-06-01 Commonwealth Scientific And Industrial Research Organisation Production of viruses in cell culture
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
KR20210132045A (ko) 2019-01-23 2021-11-03 리제너론 파마슈티칼스 인코포레이티드 안지오포이에틴-유사 7(angtl7) 억제제를 사용하는 안구 질환의 트리트먼트
CN110129281A (zh) * 2019-05-15 2019-08-16 成都天邦生物制品有限公司 一种使用悬浮细胞培养新城疫病毒的方法及应用
JP2024507943A (ja) 2021-02-26 2024-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 糖質コルチコイド及びアンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による炎症の治療
CN114774418B (zh) * 2022-04-19 2023-11-14 深圳市人民医院 shRNA分子及其在敲低TM9SF2基因表达中的应用
CN116656628A (zh) * 2023-07-31 2023-08-29 深圳市卫光生物制品股份有限公司 一种痘病毒载体疫苗的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162215A (en) 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
CA2334857C (en) 1998-06-12 2012-03-20 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
EP2316924B1 (en) 1998-06-12 2017-10-11 Icahn School of Medicine at Mount Sinai Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
EP1341914A2 (en) 2000-12-07 2003-09-10 Sangamo Biosciences Inc. Regulation of angiogenesis with zinc finger proteins
US7947469B2 (en) 2001-01-22 2011-05-24 Gendaq, Ltd. Modulation of HIV infection
EP1353941B1 (en) 2001-01-22 2013-03-13 Sangamo BioSciences, Inc. Modified zinc finger binding proteins
US7145057B2 (en) 2002-02-01 2006-12-05 Origen Therapeutics, Inc. Chimeric bird from embryonic stem cells
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
CA2595576A1 (en) 2005-02-01 2006-08-10 Origen Therapeutics, Inc. Transgenic chickens
JP5603012B2 (ja) 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
MX2009006303A (es) 2006-12-14 2009-10-21 Dow Agrosciences Llc Proteinas de dedo de zinc no canonicas optimizadas.
US9051369B2 (en) 2007-09-20 2015-06-09 Commonwealth Scientific And Industrial Research Organisation Avian cytokines and genetic sequences encoding same
WO2010107493A2 (en) 2009-03-20 2010-09-23 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
WO2011005765A1 (en) 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Bioprocessing
WO2011017293A2 (en) 2009-08-03 2011-02-10 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
EP2295543A1 (en) 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
EP2510087A2 (en) 2009-12-11 2012-10-17 The Brigham and Women's Hospital, Inc. Pathogen restriction factors
WO2012164130A1 (es) 2011-05-27 2012-12-06 Consejo Superior De Investigaciones Científicas (Csic) Construcción de células deficitarias en un modulador negativo del virus de la gripe para incrementar la producción de virus vacunales
WO2013059299A1 (en) * 2011-10-17 2013-04-25 The Uab Research Foundation Antibodies for interferon subtypes and interferon/interferon receptor ternary complex and uses thereof
AU2013204327B2 (en) 2012-04-20 2016-09-01 Aviagen Cell transfection method
WO2013166264A2 (en) * 2012-05-02 2013-11-07 University Of Georgia Research Foundation, Inc. Methods for altering virus replication
AU2013344796B2 (en) 2012-11-16 2016-11-10 Novartis Ag Use of IL-1 beta binding antibodies for treating peripheral arterial disease
JP2016506734A (ja) 2013-02-05 2016-03-07 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド ウイルス産生用の細胞株及びその使用方法
CN105121634B (zh) 2013-03-13 2019-07-26 易木农麦克斯有限公司 具有提高的病毒生产能力的细胞系及其生产方法
US9902973B2 (en) 2013-04-11 2018-02-27 Caribou Biosciences, Inc. Methods of modifying a target nucleic acid with an argonaute
GB201310031D0 (en) * 2013-06-05 2013-07-17 Pirbright Inst The Cell
GB201310432D0 (en) 2013-06-12 2013-07-24 Univ St Andrews Virus Production
CN104560864B (zh) 2014-12-22 2017-08-11 中国科学院微生物研究所 利用CRISPR‑Cas9系统构建的敲除IFN‑β基因的293T细胞系
CN104694576B (zh) 2015-03-30 2018-04-17 山东省农业科学院家禽研究所 一种沉默df‑1细胞系中ifnar1基因的方法
WO2017088018A1 (en) 2015-11-24 2017-06-01 Commonwealth Scientific And Industrial Research Organisation Production of viruses in cell culture
MX2018006386A (es) 2015-11-24 2018-11-09 Commonwealth Scient And Industrial Reseach Organisation Produccion de virus en evos aviares.

Also Published As

Publication number Publication date
US10626379B2 (en) 2020-04-21
US20220106574A1 (en) 2022-04-07
JP2019500860A (ja) 2019-01-17
US12054750B2 (en) 2024-08-06
JP7189017B2 (ja) 2022-12-13
WO2017088018A1 (en) 2017-06-01
AU2016361455A1 (en) 2018-06-21
MX2021009554A (es) 2021-09-08
CA3005989A1 (en) 2017-06-01
CN108603188A (zh) 2018-09-28
BR112018010499A2 (pt) 2018-11-13
US20190322989A1 (en) 2019-10-24
EP3380611A1 (en) 2018-10-03
KR20180081615A (ko) 2018-07-16
EP3380611A4 (en) 2020-02-12
MX2018006373A (es) 2018-11-09
US20180340153A1 (en) 2018-11-29
US11174466B2 (en) 2021-11-16
AU2023200556A1 (en) 2023-03-02
JP2023014322A (ja) 2023-01-26

Similar Documents

Publication Publication Date Title
BR112018010499A2 (pt) método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, população de células in vitro, método para produzir uma população de células, e população de células
BR112018007538A2 (pt) células exterminadoras naturais e células ilc3 e usos das mesmas
WO2016061232A3 (en) Multiplexed shrnas and uses thereof
BR112017011582A2 (pt) fibroblasto de embrião de galinha imortalizado, cultura de célula, métodos para preparação de um cef importalizado, para a replicação de um vetor viral aviário e para a preparação de uma vacina, e, vacina.
EP4349404A3 (en) Respiratory virus vaccines
BR112016024579A2 (pt) métodos para isolamento, cultura e engenharia genética de populações de célula imune para terapia adotiva
BR112017017812A2 (pt) materiais e métodos para tratamento de hemoglobinopatias
BR112013002811A2 (pt) meios básicos simplificados para cultura celular pluripotente de humano
BR112018013808A2 (pt) dinucleotídeos cíclicos para o tratamento de condições associadas à atividade de sting, tal como câncer
BR112017007770A2 (pt) cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc.
MX2020003841A (es) Métodos y composiciones para la producción de nucleósido trifosfatos y ácidos ribonucleicos.
BR112018007864A2 (pt) métodos para preparar células t para terapia de células t
BR112017018327A2 (pt) método para a expressão regulada de um complexo, planta ou célula vegetal, semente, método para modificação de uma sequência, método para alteração da expressão de pelo menos um polinucleotídeo
BR112017006469A2 (pt) composições e métodos para inibição de expressão do gene hao1 (hidroxiácido oxidase 1 (glicolato oxidase))
BR112016025516A2 (pt) composições para controle de mosquito e usos das mesmas
BR112015018493A2 (pt) Linhagens celulares para produção de vírus e métodos de uso
CO2018012099A2 (es) Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos
BR112016013387A2 (pt) composições e métodos para controle de vírus em ácaros varroa e abelhas
AR105776A1 (es) Recombinación mejorada de loci genómicos
MX2018011162A (es) Metodos de purificacion de colageno 7.
BR112018010503A2 (pt) ovo de ave, método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, ave transgênica, e método para produzir uma ave
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
BR112015018047A8 (pt) método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas
BR112017020513A2 (pt) método de produção de peixe para transplante, peixe para transplante, método de produção de espécie híbrida de peixe e espécie híbrida de peixe
SG10201909412RA (en) Composition for suppressing muscular fatty change

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]